Dimethyl fumarate as a first- vs second-line therapy in MS: Focus on B cells.

Staun-Ram, Elsebeth; Najjar, Eiman; Volkowich, Anat; Miller, Ariel.

Afiliação

Staun-Ram E; Rappaport Faculty of Medicine (E.S.-R., E.N., A.M.), Technion-Israel Institute of Technology; and the Department of Neurology (A.V., A.M.), Neuroimmunology Unit & Multiple Sclerosis Center, Carmel Medical Center, Haifa, Israel.
Najjar E; Rappaport Faculty of Medicine (E.S.-R., E.N., A.M.), Technion-Israel Institute of Technology; and the Department of Neurology (A.V., A.M.), Neuroimmunology Unit & Multiple Sclerosis Center, Carmel Medical Center, Haifa, Israel.
Volkowich A; Rappaport Faculty of Medicine (E.S.-R., E.N., A.M.), Technion-Israel Institute of Technology; and the Department of Neurology (A.V., A.M.), Neuroimmunology Unit & Multiple Sclerosis Center, Carmel Medical Center, Haifa, Israel.
Miller A; Rappaport Faculty of Medicine (E.S.-R., E.N., A.M.), Technion-Israel Institute of Technology; and the Department of Neurology (A.V., A.M.), Neuroimmunology Unit & Multiple Sclerosis Center, Carmel Medical Center, Haifa, Israel.

Neurol Neuroimmunol Neuroinflamm ; 5(6): e508, 2018 Nov.

Article em En | MEDLINE | ID: mdl-30345334

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article